Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16463642 | 0.89 | CYP3A4 (0.38) | CYP3A4ALOX15MEN1KMT2AGAA | |
| SCHEMBL8156416 | 0.84 | MEN1 (0.45) | CYP3A4ALOX15MEN1KMT2AGAA | |
| SCHEMBL9709450 | 0.81 | MEN1 (0.48) | CYP3A4ALOX15MEN1KMT2APTPN1 | |
| SCHEMBL17208400 | 0.81 | CYP3A4 (0.45) | CYP3A4ALOX15MEN1KMT2AALDH1A1 | |
| SCHEMBL16481093 | 0.80 | MEN1 (0.41) | CYP3A4ALOX15MEN1KMT2AACE2 | |
| SCHEMBL16464488 | 0.78 | GAA (0.37) | CYP3A4ALOX15MEN1KMT2AGAA | |
| SCHEMBL16463696 | 0.76 | GAA (0.33) | GAATRPC6 | |
| SCHEMBL9017168 | 0.75 | PTPN1 (0.54) | CYP3A4ALOX15MEN1KMT2APTPN1 | |
| SCHEMBL9017162 | 0.75 | PTPN1 (0.54) | CYP3A4ALOX15MEN1KMT2APTPN1 | |
| SCHEMBL16465718 | 0.75 | GAA (0.33) | GAATRPC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104704094-B | Flavor and fragrance formulation (III) | 帝斯曼知识产权资产管理有限公司 | 2020-06-23 | — | — | CN | disclosed |
| EP-2904080-B1 | FLAVOR AND FRAGRANCE FORMULATION (I) | DSM IP ASSETS BV (NL) | 2018-12-12 | — | — | EP | disclosed |
| US-20150307439-A1 | FLAVOR AND FRAGRANCE FORMULATION (I) | DSM IP ASSETS B.V. (NL) | 2015-10-29 | — | — | US | disclosed |
| EP-2904080-A2 | FLAVOR AND FRAGRANCE FORMULATION (I) | DSM IP Assets B.V. (NL) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014056851-A2 | FLAVOR AND FRAGRANCE FORMULATION (I) | DSM IP ASSETS B.V. (NL) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307439-A1 | FLAVOR AND FRAGRANCE FORMULATION (I) | NISCH, TAS2R5, FDFT1 | CYP3A4 243/4885ALOX15 178/4885MEN1 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.